Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.91 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.64 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30176973 | 0.98 | PARP1 (0.89) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL30176861 | 0.98 | PARP1 (0.89) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL22857122 | 0.98 | PARP1 (0.89) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL14621928 | 0.98 | PARP1 (0.89) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL28598382 | 0.98 | PARP1 (0.89) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL29900512 | 0.95 | PARP1 (1.00) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL168776 | 0.95 | PARP1 (1.00) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL5794718 | 0.89 | PARP1 (0.82) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL29431542 | 0.89 | PARP1 (0.82) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL30176852 | 0.86 | PARP1 (0.73) | PARP1TNKS2PDE10APARP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111592549-B | Preparation method of quinazolinone derivative | 温州大学 | 2023-05-09 | — | — | CN | claimed |
| CN-111592549-A | Preparation method of quinazolinone derivative | 温州大学 | 2020-08-28 | — | — | CN | claimed |
| CN-117486887-A | Polycyclic pyrimidine-4-ketone compound and preparation method and application thereof | 昆明学院 | 2024-02-02 | — | — | CN | disclosed |
| US-20230346815-A1 | LMP7-SELECTIVE INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS AND SOLID TUMORS | MERCK PATENT GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| EP-4225281-A1 | LMP7-SELECTIVE INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS AND SOLID TUMORS | Merck Patent GmbH (DE) | 2023-08-16 | — | — | EP | disclosed |
| CN-116528877-A | LMP7 selective inhibitors for the treatment of blood disorders and solid tumors | 默克专利股份公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-111592549-B | Preparation method of quinazolinone derivative | 温州大学 | 2023-05-09 | — | — | CN | disclosed |
| CN-112174899-B | Application of light-promoted Minisci C-H alkylation reaction in preparation of alkyl-substituted azacycle | 南开大学 | 2023-01-17 | — | — | CN | disclosed |
| CN-109384731-B | Method for preparing quinazolinone from enol | 南京理工大学 | 2021-10-08 | — | — | CN | disclosed |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2021-09-30 | — | — | US | disclosed |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2021-03-23 | — | — | US | disclosed |
| US-6534511-B1 | The use of certain 6-arylpyrazolo(3,4-d)pyrimidin-4-ones, 2 arylquinazolin-4-ones, 2-arylpurin-6-ones and 2-arylpyrido(3,2- d)pyrimidin-4-ones, or a pharmaceutically acceptable salt thereof, forsexual disorders | PFIZER INC. | 2003-03-18 | — | — | US | disclosed |
| EP-0793498-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 2002-12-11 | — | — | EP | disclosed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | disclosed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | disclosed |
| EP-0793498-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016657-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
| US-4431440-A | 2-/4-METHYLPHENYL/-4-3H-QUINAZOLINES AS HERBICIDES AND PLANT GROWTH REGULATORS; CEREALS | AMERICAN CYANAMID COMPANY (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0058822-A1 | Method to alter or control the development and/or life cycle of various plant species | AMERICAN CYANAMID COMPANY (US) | 1982-09-01 | — | — | EP | disclosed |
| US-3998951-A | Substituted 2-arylquinazolines as fungicides | FMC CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346815-A1 | LMP7-SELECTIVE INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS AND SOLID TUMORS | PSMB7, PSMA7, PSMB1 | PARP1 2540/4885TNKS2 2523/4885PDE10A 4750/4885 |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | PARP1 2220/4885TNKS2 1562/4885PDE10A 1653/4885 |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | NFKBIA, NFRKB, TFEB | PARP1 2220/4885TNKS2 1562/4885PDE10A 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.